Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||BrUOG 274: Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?|
- Understanding of all elements of informed consent via questionnaire [ Time Frame: 1 month ] [ Designated as safety issue: No ]Comprehension of the important elements of the informed consent forms using questionnaire
- Patient comprehension [ Time Frame: every 6 months, up to 1 year ] [ Designated as safety issue: No ]Effectors of patient comprehension using questionnaire
|Study Start Date:||March 2012|
|Study Completion Date:||November 2014|
|Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
Obtaining informed consent as part of a clinical study is a cornerstone of current day medical ethics; however, this has not always been the case. The development of the informed consent has been necessitated out of abuses committed in the name of medicine.
Informed consents have become increasing lengthy and complex. It is not unusual for an Oncology Clinical Research informed consent to be greater than 20 pages. Investigators will utilize the QuIC-A survey to evaluate patient understanding of the basic elements of informed consent required by federal regulations. The QuIC-A survey has been condensed from 20 questions to 14 questions by eliminating the 6 phase specific questions. The remaining 14 questions are designed irrespective of phase and address the basic elements of informed consent.
Investigators hypothesize that as informed consents have become more lengthy and complicated, in part due to required regulatory language and legal clauses inserted to protect the institution performing research, patient comprehension of the basic elements of informed consent has been hindered.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01772511
|United States, Rhode Island|
|Rhode Island Hospital|
|Providence, Rhode Island, United States, 02903|
|The Miriam Hospital|
|Providence, Rhode Island, United States, 02906|
|Principal Investigator:||Andrew Schumacher||Brown University|